On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.
Dr. Botond Roska says we should keep our eyes on gene therapy.
Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
Physician-scientist Cyndy Grosskreutz explains why she transitioned from academia to industry.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.